Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM

By afschroeder • June 21, 2025

Saberi S, Abraham TP, Choudhury L, Barriales-Villa R, Elliott PM, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats CJ, Fifer MA, Sherrid MV, Solomon SD, Watkins H, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Maron MS, Masri A; FOREST-HCM Steering Committee and Investigators. Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM. JACC Heart Fail. 2025 Jun 19;13(8):102496. doi: 10.1016/j.jchf.2025.03.040. Epub ahead of print. PMID: 40540987.

Tags: aficamten, Cardiology/Epi, Cedars Sinai DoM, Clinical Trial, efficacy, Hypertrophic cardiomyopathy, Long-term outcomes, Publications, safety

Implementing a Cardiology Quality Incentive Program to Improve Guideline-Directed Medical Therapy

Cho DJ, Bokhoor PI, Dermenchyan A, Brownell N, Delavin NL, Furlong S, Hoo J, Tibbe T, Chen LY, Vangala S, Waterman BA, Han M, Fonarow[...]

Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy

Juarez Casillas JE, Nikitas J, Rettig MB, Reiter RE, Lee A, Steinberg ML, Valle L, Kalbasi TR, Calais J, Czernin J, Eala MA, Tsai S,[...]

Towards accurate interpretation of hypothesis testing in cardiology randomised controlled clinical trials

Sharifan A, Fonarow G. Towards accurate interpretation of hypothesis testing in cardiology randomised controlled clinical trials. Heart. 2025 Jun 20:heartjnl-2025-326515. doi: 10.1136/heartjnl-2025-326515. Epub ahead of[...]